Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids.

Animals Calcium / metabolism Cricetinae Humans Indoles / chemistry Molecular Docking Simulation Molecular Structure Phenylurea Compounds / chemistry Piperidines / chemistry Pyridines / chemistry Receptor, Cannabinoid, CB1 / antagonists & inhibitors
Allosteric modulator CB(1) receptor Hybrid Molecular modelling Structure-activity relationship

Journal

Bioorganic & medicinal chemistry
ISSN: 1464-3391
Titre abrégé: Bioorg Med Chem
Pays: England
ID NLM: 9413298

Informations de publication

Date de publication:
01 07 2021
Historique:
received: 19 01 2021
revised: 22 04 2021
accepted: 07 05 2021
pubmed: 21 5 2021
medline: 9 11 2021
entrez: 20 5 2021
Statut: ppublish

Résumé

Allosteric modulation offers an alternate approach to target the cannabinoid type-1 receptor (CB

Identifiants

DOI: 10.1016/j.bmc.2021.116215 PMID: 34015703 PMC: PMC8506265
pubmed: 34015703
pii: S0968-0896(21)00223-6
doi: 10.1016/j.bmc.2021.116215
pmc: PMC8506265
mid: NIHMS1705294
pii:
doi:

Substances chimiques

1-(4-chlorophenyl)-3-(3-(6-pyrrolidin-1-ylpyridin-2-yl)phenyl)urea 0
5-chloro-3-ethyl-1H-indole-2-carboxylic acid (2-(4-piperidin-1-yl-phenyl)ethyl)amide 0
Indoles 0
Phenylurea Compounds 0
Piperidines 0
Pyridines 0
Receptor, Cannabinoid, CB1 0
Calcium SY7Q814VUP

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

116215

Subventions

Organisme : NIDA NIH HHS
ID : K01 DA045752
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA040693
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Références

Mol Pharmacol. 2005 Nov;68(5):1484-95
pubmed: 16113085
J Mol Biol. 1993 Dec 5;234(3):779-815
pubmed: 8254673
Methods Mol Biol. 2017;1654:39-54
pubmed: 28986782
J Comput Chem. 2011 Apr 15;32(5):866-77
pubmed: 20949517
Curr Opin Pharmacol. 2010 Feb;10(1):14-22
pubmed: 19942481
J Med Chem. 2011 Mar 24;54(6):1539-54
pubmed: 21344906
Nature. 1990 Aug 9;346(6284):561-4
pubmed: 2165569
Proteins. 2013 Aug;81(8):1304-17
pubmed: 23408552
Trends Pharmacol Sci. 2018 Aug;39(8):748-765
pubmed: 29885909
J Biol Chem. 2007 Nov 9;282(45):32924-34
pubmed: 17848566
Bioorg Med Chem Lett. 2013 Sep 1;23(17):4751-60
pubmed: 23902803
Pharmacol Ther. 2001 Apr;90(1):45-60
pubmed: 11448725
J Med Chem. 2017 Feb 9;60(3):1089-1104
pubmed: 28059509
Nat Protoc. 2008;3(12):1832-47
pubmed: 18989261
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4454-8
pubmed: 20160100
ACS Chem Neurosci. 2017 Oct 18;8(10):2290-2308
pubmed: 28737888
J Chem Inf Model. 2013 Jan 28;53(1):201-9
pubmed: 23268595
Sci Rep. 2015 Oct 20;5:15453
pubmed: 26482099
Life Sci. 2005 Sep 23;77(19):2339-50
pubmed: 15935395
Trends Pharmacol Sci. 2007 Feb;28(2):83-92
pubmed: 17222464
Nat Med. 2001 Oct;7(10):1151-4
pubmed: 11590440
J Med Chem. 2006 Oct 19;49(21):6177-96
pubmed: 17034125
Nat Chem Biol. 2019 Dec;15(12):1199-1205
pubmed: 31659318
J Biol Chem. 2007 Apr 6;282(14):10576-84
pubmed: 17283075
Mol Pharmacol. 1988 Nov;34(5):605-13
pubmed: 2848184
Drug Alcohol Depend. 2014 Oct 1;143:251-6
pubmed: 25169627
J Med Chem. 2006 Jan 26;49(2):534-53
pubmed: 16420040
Med Res Rev. 2010 May;30(3):463-549
pubmed: 19557759
J Med Chem. 2018 May 24;61(10):4370-4385
pubmed: 29688015
Eur J Pharmacol. 2006 Dec 28;553(1-3):1-9
pubmed: 17081515
ACS Chem Neurosci. 2019 Jan 16;10(1):518-527
pubmed: 30188693
J Org Chem. 2017 Jan 20;82(2):992-999
pubmed: 27966953
Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3353-63
pubmed: 23108552
Pharmacol Rev. 2006 Sep;58(3):389-462
pubmed: 16968947
Bioorg Med Chem. 2015 May 1;23(9):2195-2203
pubmed: 25797163
J Chem Theory Comput. 2014 Feb 11;10(2):865-879
pubmed: 24803855
Neuropharmacology. 2017 Sep 15;124:3-12
pubmed: 28527758
J Med Chem. 2014 Sep 25;57(18):7758-69
pubmed: 25162172
Nature. 2017 Jul 27;547(7664):468-471
pubmed: 28678776
J Chem Inf Model. 2018 Oct 22;58(10):2043-2050
pubmed: 30199633
Future Med Chem. 2019 Aug;11(15):2019-2037
pubmed: 31517528
Nature. 1993 Sep 2;365(6441):61-5
pubmed: 7689702
J Med Chem. 2013 Oct 24;56(20):7965-75
pubmed: 24053617
Br J Pharmacol. 2013 Oct;170(4):893-907
pubmed: 23937487
Front Mol Biosci. 2018 Feb 13;5:15
pubmed: 29487854
Curr Top Med Chem. 2019;19(16):1418-1435
pubmed: 31284863
J Med Chem. 2019 Nov 14;62(21):9806-9823
pubmed: 31596583
Biochem Pharmacol. 1995 Jun 29;50(1):83-90
pubmed: 7605349
Cell. 2016 Oct 20;167(3):750-762.e14
pubmed: 27768894
Med Res Rev. 2017 May;37(3):441-474
pubmed: 27879006
J Biol Chem. 2007 Dec 28;282(52):37529-36
pubmed: 17940290
J Chem Inf Model. 2014 Jan 27;54(1):324-37
pubmed: 24358939
Phys Chem Chem Phys. 2014 Aug 21;16(31):16719-29
pubmed: 24999761
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
Physiol Behav. 2008 Mar 18;93(4-5):666-70
pubmed: 18076956
J Med Chem. 2015 Aug 13;58(15):5979-88
pubmed: 26203658
Nat Rev Drug Discov. 2009 Jan;8(1):41-54
pubmed: 19116626
Nature. 2016 Dec 22;540(7634):602-606
pubmed: 27851727
J Med Chem. 2017 Sep 14;60(17):7410-7424
pubmed: 28792219
Neuropharmacology. 2005 Jun;48(8):1097-104
pubmed: 15910886
Br J Pharmacol. 2007 Nov;152(5):805-14
pubmed: 17592509
Br J Pharmacol. 2004 Mar;141(5):765-74
pubmed: 14744801
J Chem Inf Model. 2014 Oct 27;54(10):2697-717
pubmed: 25266271
Drug Metab Rev. 2018 Feb;50(1):3-13
pubmed: 29355030
Future Med Chem. 2016 Sep;8(14):1753-67
pubmed: 27572621
J Neurochem. 2013 Mar;124(5):584-9
pubmed: 23205875

Auteurs

Thuy Nguyen (T)

Research Triangle Institute, Research Triangle Park, NC 27709, USA.

Thomas F Gamage (TF)

Research Triangle Institute, Research Triangle Park, NC 27709, USA.

Ann M Decker (AM)

Research Triangle Institute, Research Triangle Park, NC 27709, USA.

David B Finlay (DB)

Department of Pharmacology and Toxicology, University of Otago, Dunedin 9054, New Zealand.

Tiffany L Langston (TL)

Research Triangle Institute, Research Triangle Park, NC 27709, USA.

Daniel Barrus (D)

Research Triangle Institute, Research Triangle Park, NC 27709, USA.

Michelle Glass (M)

Department of Pharmacology and Toxicology, University of Otago, Dunedin 9054, New Zealand.

Danni L Harris (DL)

Research Triangle Institute, Research Triangle Park, NC 27709, USA. Electronic address: danniharris@rti.org.

Yanan Zhang (Y)

Research Triangle Institute, Research Triangle Park, NC 27709, USA. Electronic address: yzhang@rti.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Rational design of cannabinoid type-1 receptor...
questionsmedicales.fr › Facteurs biologiques › Facteurs de la coagulation sanguine › Calcium › Rational design of cannabinoid type-1 receptor...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Arvicolinae › Cricetinae › Rational design of cannabinoid type-1 receptor...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Rational design of cannabinoid type-1 receptor...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Indoles › Rational design of cannabinoid type-1 receptor...
questionsmedicales.fr › Sciences de l'information › Méthodologies informatiques › Simulation numérique › Simulation de docking moléculaire › Rational design of cannabinoid type-1 receptor...
questionsmedicales.fr › Phénomènes chimiques › Structure moléculaire › Rational design of cannabinoid type-1 receptor...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures cycliques › Hydrocarbures aromatiques › Dérivés du benzène › Phénylurées › Rational design of cannabinoid type-1 receptor...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pipéridines › Rational design of cannabinoid type-1 receptor...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Rational design of cannabinoid type-1 receptor...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs couplés aux protéines G › Récepteurs de cannabinoïdes › Récepteur cannabinoïde de type CB1 › Rational design of cannabinoid type-1 receptor...